Immunitoai

Immunito AI (immunitoai.com) is an antibody discovery company founded in 2021 and headquartered in Bangalore, India. It applies computational, artificial-intelligence-based methods to the design of antibodies, operating an in-house biological laboratory alongside its software work so that computationally generated candidates can be produced and evaluated experimentally.

The company's platform is described as generating novel antibody sequences optimized for target binding, specificity, and developability. Researchers specify a disease target and receive candidate molecules generated in silico, which is intended to shorten lead discovery timelines and reduce the amount of laboratory screening required. No independent public source documents were available at the time of compilation, so the profile rests on internally held information only.

Founding story

The company was founded in 2021 by Aridni Shah and Trisha Chatterjee, who serve as CEO and CTO respectively. Dr. Abhishek Mathur is also associated with the company. Further details of the founding are not available in the material reviewed.

Business model

Immunito AI positions itself as a discovery partner to organizations developing antibody therapeutics, supplying computationally designed antibody candidates supported by in-house wet-lab capability. No pricing, contracting, or revenue-model details are available from the material reviewed.

Latest developments

No dated public developments could be verified; no fetchable web sources were available at the time of compilation.